EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A genome-scale adaptation map identifies the FANCM-RMI1/2 complex as an opposing modulator of cell fitness upon BRCA1 or BRCA2 loss

François Dossin, Mikael Attia, Fabricio Montero Zúñiga, Daniel González-Acosta, Rachel Brough, Fei Fei Song, Dragomir B Krastev, Maya Raghunandan, Stephen J Pettitt, Aurélien Boré, Amaury Vaysse, Raphaël Margueron und 4 weitere

Molecular Cell · 2026

DOI: 10.1016/j.molcel.2026.09.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Cell, 2026. Verfasst von François Dossin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institut Pasteur, Université Paris Cité, INSERM U1223, Équipe Labellisée Ligue Contre Le Cancer, Genome Integrity, Immunity and Cancer Unit, 75015 Pa…. Hauptthemen laut MEDLINE: BRCA2 Protein, BRCA1 Protein, DNA Helicases, DNA-Binding Proteins. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Breast Cancer Research Foundation Inc, Ligue Contre le Cancer, Institut Pasteur.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer cells lacking BRCA1 or BRCA2 must adapt to proliferate despite pervasive genomic instability. To delineate BRCA1- and BRCA2-specific adaptation landscapes, we developed an isogenic screening platform enabling acute depletion of either protein. Genetic interaction profiling revealed hundreds of genes with shared, distinct, or opposing effects in the two BRCA-deficient states. We identified FANCM as essential in BRCA1-deficient cells. Conversely, FANCM is toxic in BRCA2-deficient cells, where it promotes replication fork degradation through RMI1/2 recruitment and sensitizes cells to PARP inhibition. FANCM loss restored fork integrity and alleviated genomic instability and proliferation defects without restoring homologous recombination or suppressing single-stranded DNA (ssDNA) gaps. Finally, we report a FANCM variant that disrupts RMI1/2 binding in a BRCA2m breast cancer patient that is associated with PARP-inhibitor resistance. These findings define fundamentally distinct adaptive routes to BRCA1 and BRCA2 loss and establish FANCM-RMI1/2 as a determinant of mutation-specific vulnerabilities and therapeutic responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BRCA2 ProteinBRCA1 ProteinDNA HelicasesDNA-Binding ProteinsBreast NeoplasmsCarrier ProteinsHumansGenomic InstabilityPoly(ADP-ribose) Polymerase InhibitorsDNA ReplicationCell Line, TumorFemaleDrug Resistance, NeoplasmCell ProliferationHistone Chaperones

Stichwörter der Autor:innen

BRCA1BRCA2FANCMPARP-inhibitor resistanceRMI1/2auxin-inducible degron CRISPR screengenome stabilityreplication fork protectionsynthetic lethalitysynthetic viability

Substanzen

FANCM protein, humanBRCA2 ProteinBRCA1 ProteinBRCA2 protein, humanBRCA1 protein, humanPoly(ADP-ribose) Polymerase InhibitorsDNA HelicasesDNA-Binding ProteinsCarrier ProteinsHistone Chaperones

Autor:innen und Institutionen

  • Institut Pasteur, Université Paris Cité, INSERM U1223, Équipe Labellisée Ligue Contre Le Cancer, Genome Integrity, Immunity and Cancer Unit, 75015 Paris, France. Electronic address: francois.dossin@pasteur.fr.
  • Institut Pasteur, Université Paris Cité, INSERM U1223, Équipe Labellisée Ligue Contre Le Cancer, Genome Integrity, Immunity and Cancer Unit, 75015 Paris, France.
  • Institute of Molecular Cancer Research, University of Zurich, 8050 Zürich, Switzerland.
  • Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
  • CRISPR'iT Genetic Platform Screening, Institut Curie, INSERM U934, CNRS UMR3215, 75005 Paris, France.
  • Institut Pasteur, Université Paris Cité, INSERM U1223, Équipe Labellisée Ligue Contre Le Cancer, Genome Integrity, Immunity and Cancer Unit, 75015 Paris, France; Institut Pasteur, Université Paris Cité, Bioinformatics a…

Förderung

  • The Breast Cancer Research Foundation Inc
  • Ligue Contre le Cancer
  • Institut Pasteur
  • Promex Stiftung fur die Forschung
  • H2020 Marie Skłodowska-Curie Actions
  • Institut National de la Santé et de la Recherche Médicale
  • Breast Cancer Now
  • Cancer Research UK

Zitieren

APA

Dossin, F., Attia, M., Montero Zúñiga, F., González-Acosta, D., Brough, R., Song, F. F., Krastev, D. B., Raghunandan, M., Pettitt, S. J., Boré, A., Vaysse, A., Margueron, R., Lopes, M., Tutt, A. N. J., Lord, C. J., & Deriano, L. (2026). A genome-scale adaptation map identifies the FANCM-RMI1/2 complex as an opposing modulator of cell fitness upon BRCA1 or BRCA2 loss. Molecular Cell. https://doi.org/10.1016/j.molcel.2026.09.017

Vancouver

Dossin F, Attia M, Montero Zúñiga F, González-Acosta D, Brough R, Song FF, et al. A genome-scale adaptation map identifies the FANCM-RMI1/2 complex as an opposing modulator of cell fitness upon BRCA1 or BRCA2 loss. Molecular Cell. 2026. doi:10.1016/j.molcel.2026.09.017

BibTeX
@article{Dossin2026,
  author = {Dossin, François and Attia, Mikael and Montero Zúñiga, Fabricio and González-Acosta, Daniel and Brough, Rachel and Song, Fei Fei and Krastev, Dragomir B and Raghunandan, Maya and Pettitt, Stephen J and Boré, Aurélien and Vaysse, Amaury and Margueron, Raphaël and Lopes, Massimo and Tutt, Andrew N J and Lord, Christopher J and Deriano, Ludovic},
  title = {A genome-scale adaptation map identifies the FANCM-RMI1/2 complex as an opposing modulator of cell fitness upon BRCA1 or BRCA2 loss},
  journal = {Molecular Cell},
  year = {2026},
  doi = {10.1016/j.molcel.2026.09.017}
}
Kostenlos starten →